Drug interactions with complementary medicines
Health professionals are expected to be familiar with common and clinically significant complementary medicine interactions or at least know where to look them up. Knowing the dynamic and kinetic interactions associated with commonly used complementary medicines helps to identify the risk of drug interactions. Although information on complementary medicine interactions is not readily provided by the manufacturers, evidence is available by way of case reports, independent research and web-based resources, which have increased in recent years. Collectively, these data make interactions with complementary medicines largely predictable and therefore preventable.
Key words: drug interactions, St John's wort.
Aust Prescr 2010;33:177-80
The Therapeutic Goods Administration refers to complementary medicines as 'medicinal products containing herbs, vitamins, minerals, nutritional supplements, homoeopathic medicines, traditional medicines and certain aromatherapy products'.1In Australia, complementary medicines are largely regulated as unscheduled medicines, and are usually self-selected.
Complementary medicines are very popular among Australians, with surveys indicating that up to 60% of people use at least one complementary medicine on a regular basis. However, about 50% of consumers also report using a conventional medicine on the same day as their complementary medicine.2,3It is not surprising, therefore, that healthcare professionals and consumers alike are concerned about the potential for drug interactions between these medicines.
As so many Australians use complementary medicines, including children, the elderly, patients with chronic disease, mental health disorders and cancer, it is important that prescribers always ask what complementary products their patients are taking in addition to any conventional medicines. Knowing this, and extrapolating reported pharmacodynamic and pharmacokinetic outcomes, can help predict potential drug interactions.
Complementary medicines are frequently used in the context of polypharmacy. A study of 3070 elderly people found that 74.2% took at least one prescription drug and one complementary medicine, with 32.5% of them using three or more prescription medicines with three or more complementary medicines.4This translates to an increased risk of drug interactions. In a study of 458 US Veterans' Administration patients, 197 of them reported taking complementary medicines combined with prescription medicines. Of these patients, 45% had potential for interactions, which was rated as serious in 6% of patients.5In another study which interviewed 3000 people (aged 57−85) about prescription, over-the-counter and complementary medicine use, 4% of them were potentially at risk of a major drug–drug interaction.6It has been suggested that once a patient is on eight or more medicines, regardless of origin, there is a 100% chance of a drug interaction occurring.7
As with other drugs, complementary medicine interactions can be broadly classified by their mechanism, that is, pharmacodynamic and pharmacokinetic. The former are due to overlap of pharmacological actions, while the latter result from changes in absorption, distribution, metabolism or excretion.
Risk factors for significant complementary medicine interactions are the same as for conventional medicines. These include patient characteristics (such as extremes of age, frailty, female gender, cognition, comorbities and genetic disposition) and medication factors (such as high medication burden, recent changes in medicines, drugs with a low therapeutic index and limited elimination pathways).
Due to their complex chemical structure, herbal medicines are prone to interactions via the oxidative cytochrome P450 system or the efflux drug transporter P-glycoprotein.8,9In vitroassays, using human tissue or cell lines, are frequently used to determine whether a herb affects these enzymes.10However,in vitrofindings do not necessarily correlate with what happens in the human body. As several herbal medicines and many prescription drugs are substrates, inducers or inhibitors of CYP isoenzymes or P-glycoprotein, interactions can ensue when they are used concomitantly.9A classic example is St John's wort, which has kinetic interactions with a wide range of drugs via the induction of CYP1A2, CYP3A4, CYP2C9 and P-glycoprotein.11This lowers the concentration of the concomitant drug.
Table 18,11,13,14shows selected documented interactions which have been chosen based on a composite of:
- the most frequently used complementary medicines in Australia, from survey and sales data12
- interactions with serious or clinically significant outcomes.
Table 1 8,11,13,14categorises interactions by their possible outcome, severity, supporting evidence and proposed mechanism. Generic guidance on interaction management is given in the key, within the definitions of severity (major, moderate, minor). Certain therapeutic drug classes appear repeatedly in the table such as antiplatelet drugs, anticoagulants, antidepressants, antihypertensives, hypoglycaemics, immunosuppressants, antiretrovirals and hormones. Health professionals should monitor patients closely when a complementary medicine is taken concomitantly with these drugs.
Evidence-based complementary medicine interactions8,11,13,14
This table shows complementary medicines with at least one 'major' interaction.
|Complementary medicine||Interacting drug||Possible outcome||Severity and level of evidence*||Proposed mechanisms/comment|
|Black cohosh||Cisplatin||↓ cytotoxic effect||Moderate, level D||Animal data only|
|Hepatotoxic drugs e.g. high-dose paracetamol, alcohol||↑ risk of hepatotoxicity||Moderate, level D||Pharmacodynamic additive risk|
|CYP2D6 substrates e.g. amitriptyline||↑ substrate levels and drug effect||Moderate, level B||Moderate inhibitor of CYP2D6|
|Calcium||Quinolone antibiotics, sotalol, tetracycline, thyroxine||↓ drug effect||Moderate, level B||Formation of insoluble salts and decreased absorption|
|Celery seed||Thyroxine||↓ drug level and effect||Moderate, level D||Mechanism unknown but two case reports|
|Chamomile (German)||CYP1A2 and CYP3A4 substrates||↑ drug levels||Moderate, level D||Theoretical|
|CNS depressants||↑ drug effect||Moderate, level D||Additive sedative effects|
|Coenzyme Q10||Chemotherapy (e.g. alkylating drugs)||↓ cytotoxic effect||Moderate, level B||May counteract cytotoxic oxidative stress|
|Antihypertensives||↑ drug effect||Moderate, level B||Coenzyme Q10 has an antihypertensive effect|
|Warfarin||↓ drug effect||Moderate, level D||Coenzyme Q10 may have vitamin K-like effects|
|Cranberry||Warfarin||↑ drug effect||Moderate, level B||Cranberry has variable effects on CYP3A4, CYP2C9, CYP1A2|
|Echinacea||CYP1A2 and CYP3A4 substrates e.g. clopidogrel (prodrug), olanzapine, warfarin||↑ substrate levels||Moderate, levels B and D respectively||Inhibition of CYP1A2 and CYP3A4|
|Evening primrose oil||Antiplatelet drugs, warfarin||↑ drug effect||Major, level B||Contains gamma-linolenic acid, probable anticoagulant|
|Fenugreek||Hypoglycaemic drugs||↑ drug effect||Moderate, level B||Additive hypoglycaemic effect|
|Antiplatelet drugs, warfarin||↑ bleeding risk||Moderate, level D||Antiplatelet activity|
|Fish oil||Antihypertensive drugs||Additive blood pressure lowering||Moderate, level B||Additive blood pressure-lowering effect found with some antihypertensives.|
|Antiplatelet drugs, warfarin||↑ bleeding risk||Minor, level B||Antiplatelet activity in high dose|
|Contraceptives, oral||↓ fish oil effects||Moderate, level B||May decrease triglyceride-lowering effects|
|Garlic||Contraceptives, oral||↓ drug effect||Moderate, level D||Induces CYP3A4|
|Saquinavir/non-nucleoside reverse transcriptase inhibitors||↓ drug levels and effect||Major, level B||Induces CYP3A4|
|Antiplatelet drugs, warfarin||↑ bleeding risk||Moderate, level D||Theoretical antiplatelet activity|
|Ginger||Antiplatelet drugs, warfarin||↑ bleeding risk||Moderate, level B||Antiplatelet activity|
|Ginseng (Panax)||Hypoglycaemic drugs||↓ blood glucose||Moderate, level B||Hypoglycaemic effect. Conflicting evidence.|
|Immunosuppressants e.g. azathioprine||↓ drug effect||Moderate level B||Largely theoretical|
|CYP2D6 substrates||↑ substrate levels||Moderate, level B||CYP2D6 inhibitor but conflicting evidence|
|Stimulants e.g. caffeine||↑ drug effects||Moderate, level B||Additive pharmacodynamic effect|
|Ginkgo||Anticonvulsants||↑ seizure risk||Moderate, level D||Large amounts of ginkgotoxin can cause neurotoxicity|
|Warfarin, antiplatelet drugs||↑ bleeding risk||Major, level D||Antiplatelet activity after several weeks|
|CYP2C9 substrates e.g. glipizide, warfarin, celecoxib||↑ substrate levels||Moderate, level D||Inhibits CYP2C9 activity|
|CYP1A2, CYP2C19, CYP2D6 and CYP3A4 substrates||↑ substrate levels||Moderate, level B||Potentially inhibits these enzymes|
|Hypoglycaemic drugs||↑ ↓ drug effect||Moderate, level B||Variably affects blood glucose concentrations|
|Glucosamine||Warfarin||↑ bleeding risk||Major, level D||Several case reports of increased INR|
|Hawthorn||Calcium channel blockers, nitrates, phosphodiesterase inhibitors||↑ drug effect||Major, level D||Additive vasodilator effects|
|Digoxin, beta blockers||↑ drug effect||Major, level D||Additive effects on heart rate and/or blood pressure. Hawthorn has cardiotonic effects.|
|Kava||CNS depressants||↑ drug effect||Major, level A||Additive somnolence|
|CYP1A2, CYP2D6, CYP2C9, CYP2E1, CYP3A4 substrates||↑ substrate levels||Moderate, level B||Kava potentially inhibits these enzymes |
|P-glycoprotein substrates||↑ substrate levels||Moderate, level D|
|Lactobacillus acidophilus||Immunosuppressants||↑ risk of infection||Moderate, level D|
|Antibiotics||↓ drug effect||Moderate, level D|
|Milk thistle||CYP2C9 substrates e.g. amitriptyline, phenytoin, warfarin||↑ drug effect||Moderate, level B||Inhibits CYP2C9, glucuronidase and organic anion transporting polypeptide 1B1. Conflicting evidence.|
|Noni juice||Warfarin||↓ drug effect||Moderate, level D||Contains vitamin K|
|Olive leaf||Antihypertensive drugs||↑ drug effect||Moderate, level B||Additive antihypertensive effects|
|Hypoglycaemic drugs||↑ drug effect||Moderate, level B||Additive hypoglycaemic effects|
|Psyllium||Carbamazepine, lithium||↓ drug effect||Moderate, level D||Decreases gastrointestinal absorption of other drugs|
|Hypoglycaemic drugs||↑ drug effect||Moderate, level B||Additive hypoglycaemic effects|
|Selenium||Antiplatelet drugs, warfarin||↑ drug effect||Moderate, level D||Selenium dose of 10 microgram/kg/day can increase bleeding time|
|Statins, niacin||↓ drug effect||Moderate, level A||Selenium plus beta carotene, vitamins C and E decreased the lipid-lowering effect|
|Senna||Digoxin, diuretics||↑ drug effect||Moderate, level D||Additive potassium loss with long-term use or high doses of senna|
|St John's wort||Alprazolam||↓ drug levels & effect||Major, level B||Increased clearance; half-life reduced by 50%|
|Amitriptyline||↑ drug effect||Major, level B||Increased risk of serotonin syndrome |
|Antidepressants, tramadol||↑ drug effect||Major, level D|
|Pethidine||↑ drug effect||Major, level D|
|Triptans||↑ drug effect||Moderate, level D|
|Clopidogrel||↑ bleeding risk||Moderate, level B||Increased conversion to active metabolite|
|CYP1A2, CYP2C9, CYP3A4 substrates e.g. imatinib, indinavir, tacrolimus, carbamazepine, phenytoin||↓ drug levels & effect||CYP3A4 =Major, level B CYP1A2, CYP2C9 = Moderate, level B||Induces CYP enzymes|
|Non-nucleoside reverse transcriptase inhibitors, protease inhibitors||↓ drug levels & effect||Major, level B||Induces CYP3A4|
|Oral contraceptives||↓ drug levels||Major, level B||Risk of breakthrough bleeding/contraceptive failure|
|P-glycoprotein substrates e.g. digoxin, fexofenadine, irinotecan||↓ drug levels & effect||Major, level B||Induces intestinal P-glycoprotein|
|Simvastatin||↓ drug levels||Moderate, level B||Statin levels reduced by up to 28%|
|Warfarin||↓ drug effect||Major, level B||Induces CYP1A2, CYP2C9 and CYP3A4|
|Valerian||Alprazolam||↑ drug levels||Major, level B||CYP3A4 inhibitor. Alprazolam increased by 19% in one study.|
|CNS depressants||↑ drug effect||Major, level D||Pharmacodynamic effect|
|CYP3A4 substrates||↑ substrate effect||Moderate, level D|
|Vitamin E||Antiplatelet ,warfarin||↑ bleeding risk||Moderate, level B||Antiplatelet activity|
|Chemotherapy||↓ drug effect||Moderate, level D||Possible antagonism of oxidative stress|
international normalised ratio
central nervous system
|* Interaction rating adapted from Natural Medicines Comprehensive Database.11 The level of severity (major, moderate, minor) has been calculated using the evidence and probability of harm. This rating is linked with a generic recommendation for management.|
|Major||Strongly discourage patients from using this combination as a serious adverse outcome could occur. If used, patient should be monitored closely for potential adverse outcomes.|
|Moderate||Use cautiously or avoid combination as a significant adverse outcome could occur. If used, monitor for potentialadverse outcomes.|
|Minor||Be aware that there is a chance of an interaction. Advise patients of symptoms that may occur and an action planto follow.|
Level of evidence ratings:
AHigh-quality randomised controlled trial or meta-analysis
BNon-randomised clinical trial, literature review, clinical cohort or case-control study, historical control or epidemiologic study
CConsensus or expert opinion
DAnecdotal evidence; in vitro or animal study or theoretical based on pharmacology
Finding information about complementary medicine interactions
Most complementary medicines are listed (AUST L) medicines, which are not subjected to the same rigorous premarketing safety and efficacy trials as registered (AUST R) medicines. Thus evidence of their interaction potential is often not available. In addition, manufacturers are not obliged to provide a consumer medicine information leaflet with advice or warnings regarding complementary medicine interactions.
Despite the lack of hard data, health professionals still need to make reasonable recommendations to patients about potential interactions. With a view to helping Australians make more informed decisions about using complementary medicines, an independent consortium from Mater Health Services Brisbane, Bond University and University of Queensland, with funding from the National Prescribing Service, evaluated complementary medicines information resources in 2008.12Specific criteria were used to identify 52 resources – 26 of these were shortlisted and assessed for technical quality, content and clinical utility. The quality of drug interaction information was also assessed in the review, specifically whether mechanisms were outlined, degree of severity was stated, and whether the absence of known drug interactions was disclosed. While many resources (free or subscription) had technical strengths, few had comprehensive interaction coverage. Those with some detail are included for further reading. Two of the highest ranked resources were online subscription databases, both of which contained reasonably comprehensive complementary medicine–drug interaction checkers. These were:
Consumers frequently use complementary medicines in combination with conventional medicines. For this reason, health professionals should always consider the potential for pharmacodynamic and pharmacokinetic interactions between them. High quality evidence is increasingly available for identification and prevention of these interactions.
- Therapeutic Goods Administration. The regulation of complementary medicines in Australia – an overview. 2006 Apr, updated 2007 Apr 24.
www.tga.gov.au/cm/cmreg-aust.htm[cited 2010 Jul 27]
- Kotsirilos V. GPs' attitudes toward complementary medicine. Aust Fam Phys 2007;36:270-1.
- Australian Bureau of Statistics. Complementary therapies. Australian Social Trends, 2008. Paper 4102.0.
www.abs.gov.au/AUSSTATS/abs@.nsf/Lookup/4102.0Chapter5202008[cited 2010 Jul 27]
- Nahin RL, Pecha M, Welmerink DB, Sink K, DeKosky ST, Fitzpatrick AL. Concomitant use of prescription drugs and dietary supplements in ambulatory elderly people. J Am Geriatr Soc 2009;57:1197-205.
- Peng CC, Glassman PA, Trilli LE, Hayes-Hunter J, Good CB. Incidence and severity of potential drug-dietary supplement interactions in primary care patients: an exploratory study of 2 outpatient practices. Arch Intern Med 2004;164:630-6.
- Qato DM, Alexander GC, Conti RM, Johnson M, Schumm P, Lindau ST. Use of prescription and over-the-counter medications and dietary supplements among older adults in the United States. JAMA 2008;300:2867-78.
- Cadieux RJ. Drug interactions in the elderly. Postgrad Med 1989;86:179-86.
- Boullata J. Natural health product interactions with medication. Nutr Clin Pract 2005;20:33-51.
- Interactions. In: Dietary supplements – a framework for evaluating safety. Institute of Medicine. Washington, DC: The National Academies Press; 2005. p. 235-46.
www.nap.edu/books/0309091101/html[cited 2010 Jul 27]
- MacGregor JT , Collins JM, Sugiyama Y, Tyson CA, Dean J, Smith L,et al. In vitro human tissue models in risk assessment: report of a consensus-building workshop. Toxicol Sci 2001;59:17-36.
- Jellin JM, editor. Natural medicines comprehensive database.www.naturaldatabase.com. [cited 2010 Jul 27]
- McGuire TM, Walters JA, Dean AJ, Van Driel M, Del Mar C, Kotsirilos V, et al. Review of the quality of complementary medicines information resources: summary report. Sydney: National Prescribing Service; 2009.
www.nps.org.au/__data/assets/pdf_file/0005/69656/CMsInfoSummary.pdf [cited 2010 Jul 27]
- Bjerrum L, Lopez-Valcarcel B, Petersen G. Risk factors for potential drug interactions in general practice. Eur J Gen Pract 2008;14:23-9.
- Barnes J, Anderson LA, Phillipson JD. Herbal interactions. Pharm J 2003; 270:118-21.
Barnes J, Anderson LA, Phillipson JD. Herbal medicines. 3rd ed. London: Pharmaceutical Press; 2007. (also part of MedicinesComplete,www.medicinescomplete.com)
Stockley's Drug Interactions. Baxter K, editor. 9th ed. London: Pharmaceutical Press; 2010. (also part of MedicinesComplete, www.medicinescomplete.com)
Braun L, Cohen M. Herbs and natural supplements: an evidence-based guide. 3rd ed. Sydney: Elsevier Australia; 2010.
The review of natural products. Facts & Comparisons.
Natural & alternative treatments. EBSCO.
https://healthlibrary.epnet.com/GetContent.aspx?token=af362d97-4f80-4453-a175-02cc6220a387&chunkiid=120459[cited 2010 Jul 27]
Kuhn MA, Winston D. Winston and Kuhn's herbal therapy and supplements: a scientific and traditional approach. 2nd ed. Philadelphia: Lippincott Williams and Wilkins; 2008.
Therapeutic Goods Administration. New labelling requirements and consumer information for medicines containing Black cohosh. Update 29 May 2007.
www.tga.gov.au/cm/0705blkcohosh.htm[cited 2010 Jul 27]
Therapeutic Goods Administration. Kava – safety alerts & advisory statements.
www.tga.gov.au/alerts/kava.htm[cited 2010 Jul 27]
Conflict of interest: none declared
First published online 1 December 2010